Samir V. Parikh, MD, FASN - Emerging Therapeutic Options for Lupus Nephritis: Preserving Kidney Function and Delaying Progression

episode

CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

ON-AIR 🟢 - Poo-tane Gas 50 min · 23 Sep 2026 · The Morning Rumble

Lemon LIVE at 5: Trump's Attack on the Media is an Attack on Democracy 57 min · 23 Sep 2026 · The Don Lemon Show

Iran's President Addresses the UN General Assembly 3 min · 23 Sep 2026 · Fox News Hourly Update

NPR News: 09-23-2026 6PM EDT 5 min · 23 Sep 2026 · NPR News Now

Matheson on Guerrero Jr.'s contract comments, his season performance and the optics of the statement 10 min · 23 Sep 2026 · OverDrive

H3 Tim Grunhard 39 min · 23 Sep 2026 · The Program

Report any issue

Source

Recorded16 Dec 2025

Publisherc.answersincme.com ↗

Handlerec:14699036

Show notes

Please visit answersincme.com/VTG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lupus nephritis (LN) discusses the latest evidence and guidance on using biologic therapies in this patient population. Upon completion of this activity, participants should be better able to: Discuss the rationale for adding a biologic agent to standard immunosuppressive therapy to improve outcomes in LN; Review the clinical evidence for available and emerging B-cell biologic agents in LN; and Identify patients with LN who are candidates to receive biologic add-on therapy.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in